Glutathione therapy and bringing experts together to advance neuroblastoma treatment

The company began with distribution of glutathione therapy that helps patients whose tissue and intracellular levels of endogenous glutathione have been reduced by chemotherapy drugs, exacerbating the tumor condition caused by oxidative stress. Preclinical and clinical studies have demonstrated the protective role of glutathione in many pathological situations that cause cellular damage. In the same year, the company imports and distributes nationwide a therapy that reduces the incidence of hemorrhagic cystitis caused by the action of cyclophosphamide and ifosfamide. The therapy helps protect the bladder lining from the harmful effects of these two drugs, which the body breaks down into substances that can damage the bladder. The company sponsored an expert meeting in Belgrade, where the main topic was treatment of neuroblastoma in children with domestic and international experts, where the latest research results in this field were presented and previous experiences were shared in order to improve the future application of the therapy for this rare disease.